Read by QxMD icon Read


Kristina Wachter, Samir Ahad, Christian J Rustenbach, Ulrich F W Franke, Hardy Baumbach
BACKGROUND: Transcatheter aortic valve implantation (TAVI) has proven to be a valid option for patients with severe aortic stenosis who are at high perioperative risk, particularly in patients with previous cardiac surgery. Several patients with previous mitral valve surgery were reported to have been successfully treated with TAVI. CASE PRESENTATION: Two patients, one with mechanical and one with biological mitral valve prosthesis, presented with symptomatic severe aortic stenosis...
2016: Journal of Cardiothoracic Surgery
Miriam Silaschi, Hendrik Treede, Ardawan J Rastan, Hardy Baumbach, Friedhelm Beyersdorf, Utz Kappert, Walter Eichinger, Florian Rüter, Thomas L de Kroon, Rüdiger Lange, Stephan Ensminger, Olaf Wendler
OBJECTIVES: Transcatheter aortic valve replacement (TAVR) is an established therapy for patients with aortic stenosis (AS) at high surgical risk. The JenaValve™ is a second-generation, self-expanding transcatheter heart valve (THV), implanted through transapical access (TA). During stent deployment, a specific 'clipping-mechanism' engages native aortic valve cusps for fixation. We present 1-year outcomes of the JUPITER registry, a post-market registry of the JenaValve for TA-TAVR. METHODS: The JUPITER registry is a prospective, multicentre, uncontrolled and observational European study to evaluate the long-term safety and effectiveness of the Conformité Européenne-marked JenaValve THV...
May 30, 2016: European Journal of Cardio-thoracic Surgery
Andreas Schaefer, Hendrik Treede, Moritz Seiffert, Florian Deuschl, Niklas Schofer, Yvonne Schneeberger, Stefan Blankenberg, Hermann Reichenspurner, Ulrich Schaefer, Lenard Conradi
BACKGROUND: Paravalvular leakage (PVL) is a known complication of transcatheter aortic valve implantation (TAVI) and is associated with poor outcome. Besides balloon-post-dilatation, valve-in-valve (ViV) procedures can be taken into consideration to control this complication. Herein we present initial experience with use of the latest generation balloon-expandable Edwards Sapien 3® (S3) transcatheter heart valve (THV) for treatment of failing THVs. METHODS: Between 01/2014 and 12/2014 three patients (two male, age: 71-80 y, log EUROScore I: 11...
2016: Journal of Cardiothoracic Surgery
Juan Mieres, Marcelo Menéndez, Carlos Fernández-Pereira, Miguel Rubio, Alfredo E Rodríguez
Transcatheter Aortic Valve Replacement (TAVR) is performed in patients who are poor surgical candidates. Many patients have inadequate femoral access, and alternative access sites have been used such as the transapical approach discussed in this paper. We present an elderly and fragile patient not suitable for surgery for unacceptable high risk, including poor ventricular function, previous myocardial infarction with percutaneous coronary intervention, pericardial effusion, and previous cardiac surgery with replacement of mechanical mitral valve...
2015: Case Reports in Cardiology
Buntaro Fujita, Smita Scholtz, Stephan Ensminger
Coronary obstruction during transcatheter aortic valve implantation is a potentially life-threatening complication. Most of the widely used transcatheter heart valves require a certain distance between the basal aortic annular plane and the origins of the coronary arteries. We report the case of a successful valve-in-valve procedure with an Edwards SAPIEN XT valve into a JenaValve as a bail-out procedure in a patient with a low originating left coronary artery and a heavily calcified aorta.
April 2016: Catheterization and Cardiovascular Interventions
Karim Ibrahim, Silvio Quick, Utz Kappert, Ruth H Strasser, Robin H Heijmen, Olaf Wendler
No abstract text is available yet for this article.
July 2015: EuroIntervention
Moritz Seiffert, Buntaro Fujita, Maxim Avanesov, Clemens Lunau, Gerhard Schön, Lenard Conradi, Emir Prashovikj, Smita Scholtz, Jochen Börgermann, Werner Scholtz, Ulrich Schäfer, Gunnar Lund, Stephan Ensminger, Hendrik Treede
AIMS: Calcification of the device landing zone is linked to paravalvular regurgitation after transcatheter aortic valve implantation (TAVI). The mechanisms remain incompletely understood and the performance of next-generation transcatheter heart valves (THV) has not been investigated. We evaluated the impact of calcification patterns on residual aortic regurgitation (AR) after TAVI with different THV in patients with severe aortic stenosis. METHODS AND RESULTS: TAVI was performed in 537 patients at two centres...
May 2016: European Heart Journal Cardiovascular Imaging
Oliver Reuthebuch, Luca Koechlin, Beat A Kaufmann, Arnheid Kessel-Schaefer, Brigitta Gahl, Friedrich S Eckstein
OBJECTIVE: Since the first transcatheter aortic valve implantation (TAVI) in 2002, TAVI technique has gained an increasing popularity especially in high-risk patients. In this study, we present the first echocardiographic midterm outcome with the second-generation transapical JenaValve TAVI system (JenaValve Technology GmbH, Munich, Germany) in patients with aortic stenosis (AS). METHODS: Between November 2011 and November 2012, a total of 28 patients received transapical TAVI using the JenaValve...
September 2015: Thoracic and Cardiovascular Surgeon
Unal Aydin, Mehmet Gul, Serkan Aslan, Emre Akkaya, Aydin Yildirim
Transcatheter valve implantation is a novel interventional technique, which was developed as an  alternative therapy for surgical aortic valve replacement in inoperable patients with severe aortic stenosis. Despite limited experience in using transcatheter valve implantation for mitral and aortic regurgitation, transapical transcatheter aortic valve implantation and valve-in-valve implantation for degenerated mitral valve bioprosthesis can be performed in high-risk patients who are not candidates for conventional replacement surgery...
2015: Heart Surgery Forum
Johannes Blumenstein, Won-Keun Kim, Christoph Liebetrau, Luise Gaede, Joerg Kempfert, Thomas Walther, Christian Hamm, Helge Möllmann
OBJECTIVE: Since the beginning of the transcatheter aortic valve implantation (TAVI) era, many prosthetic valves have entered clinical practice. TAVI prostheses differ regarding stent design and some may potentially interfere with diagnostic or interventional catheters. The aim of our analysis was to evaluate the feasibility of coronary angiography (CA) or percutaneous coronary intervention (PCI) in patients with prior TAVI. METHODS: From 2011 to 2014, 1,000 patients were treated by TAVI at our center using eight different valve prostheses (Symetis ACURATE TA and ACURATE TF; Medtronic CoreValve and Engager; JenaValve, SJM Portico; Edwards Lifesciences SAPIEN and SAPIEN XT)...
August 2015: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
V J Nijenhuis, M J Swaans, V Michiels, T de Kroon, R H Heijmen, J M Ten Berg
AIMS: Since the introduction of transcatheter aortic valve implantation (TAVI), newer generation and novel devices such as the retrievable JenaValve™ have been developed. We evaluated the procedural and 6-month results of our first experience with implantation of the JenaValve™. METHODS AND RESULTS: From June 2012 to December 2013, 24 consecutive patients (mean age 80 ± 7 years, 42 % male) underwent an elective transapical TAVI with the JenaValve™. Device success was 88 %...
January 2015: Netherlands Heart Journal
Daniel Kretzschmar, Alexander Lauten, Bjoern Goebel, Torsten Doenst, Tudor C Poerner, Markus Ferrari, Hans R Figulla, Ali Hamadanchi
PURPOSE: The assessment of aortic annular size is critical, and inappropriate sizing is thought to be a main reason of paravalvular aortic regurgitation. Multidetector computed tomograph is associated with the risk of contrast nephropathy. For optimal evaluation of the complex structure of the aortic annulus, three-dimensional (3D)-methods should be used. We therefore sought to determine the value of 3D-transoesophageal echocardiography (3D-TEE) for appropriate sizing. METHODS: Hundred and one patients (mean age 81·4 years) with symptomatic aortic valve stenosis (AS) and high surgical risk profile (mean log...
March 2016: Clinical Physiology and Functional Imaging
Oliver Reuthebuch, Devdas Thomas Inderbitzin, Florian Rüter, Raban Jeger, Christoph Kaiser, Peter Buser, Jens Fassl, Friedrich S Eckstein
OBJECTIVE: We present the post-CE(Conformité Européenne)-mark single-center implantation experience and short-term outcome with the second-generation transapical JenaValve transcatheter aortic valve implantation system. METHODS: Patients [N = 27; 9 women; mean (SD) age, 80.3 (5.5) years] were operated on between November 2011 and August 2012. Via a transapical approach, the valve was positioned, in some cases, repositioned, and finally implanted. All data were collected during the hospital stay...
September 2014: Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery
Yoshiki Sawa
While transcatheter aortic valve replacement( TAVR) has spread rapidly all over the world for highrisk patients with severe aortic stenosis (AS), SAPIEN XT was approved in Japan in October 2013. Since that, approximately 400 TAVR cases were performed in Japan. In our institute, we have performed 164 cases since first case in Japan in 2009 and have achieved satisfactory early results(30-day mortality:1.2%). At the same time, however, simultaneously various TAVR-related complications including a paravalvular leak, stroke, vascular complications, and coronary obstruction were observed...
July 2014: Kyobu Geka. the Japanese Journal of Thoracic Surgery
Moritz Seiffert, Ralf Bader, Utz Kappert, Ardawan Rastan, Stephan Krapf, Sabine Bleiziffer, Steffen Hofmann, Martin Arnold, Klaus Kallenbach, Lenard Conradi, Friederike Schlingloff, Manuel Wilbring, Ulrich Schäfer, Patrick Diemert, Hendrik Treede
OBJECTIVES: This analysis reports on the initial German multicenter experience with the JenaValve (JenaValve Technology GmbH, Munich, Germany) transcatheter heart valve for the treatment of pure aortic regurgitation. BACKGROUND: Experience with transcatheter aortic valve implantation (TAVI) for severe aortic regurgitation is limited due to the risk of insufficient anchoring of the valve stent within the noncalcified aortic annulus. METHODS: Transapical TAVI with a JenaValve for the treatment of severe aortic regurgitation was performed in 31 patients (age 73...
October 2014: JACC. Cardiovascular Interventions
Lenard Conradi, Moritz Seiffert, Kazuo Shimamura, Johannes Schirmer, Stefan Blankenberg, Hermann Reichenspurner, Patrick Diemert, Hendrik Treede
BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become routine for the treatment of high-risk patients with aortic stenosis. We assessed safety and feasibility of a left ventricular apical access and closure device combined with second-generation transapical (TA) TAVI transcatheter heart valves (THV). METHODS AND RESULTS: Three elderly, comorbid patients (logEuroSCORE I 13.0-31.1%) received transapical aortic valve implantation (TA-AVI) via the Apica ASC device (Apica Cardiovascular Ltd...
September 2014: Thoracic and Cardiovascular Surgeon
Friederike Schlingloff, Ulrich Schäfer, Christian Frerker, Michael Schmoeckel, Ralf Bader
OBJECTIVES: The second-generation Jenavalve prosthesis (Jenavalve Technology, Inc., Munich, Germany) is the first transcatheter valve Conformité Européene (CE) marked for treatment of both aortic stenosis (AS) and pure aortic regurgitation (AR). Although the feasibility of the Jenavalve transcatheter aortic valve implantation (TAVI) in patients with pure AR has been described, haemodynamic and follow-up data are lacking. METHODS: We report on a series of 10 transapical Jenavalve implantations for pure AR between December 2012 and September 2013...
September 2014: Interactive Cardiovascular and Thoracic Surgery
Tomokazu Kawashima, Fumi Sato
Visualizing the anatomy of the atrioventricular (AV) conduction axis substantiates that there is remarkable inter-individual variation at the macro- and microscopic levels, and that the atrioventricular bundle and left bundle branch are located more anteriorly, distally, and cranially and much closer to the aortic root complex than previously thought. The AV conduction system may therefore be compromised during implantation of a transcatheter aortic valve prosthesis, which may account for the relatively high incidence of new cardiac conduction abnormalities when conventional prosthetic valves are used...
June 1, 2014: International Journal of Cardiology
Laurens Willem Wollersheim, Riccardo Cocchieri, Petr Symersky, Bas A de Mol
No abstract text is available yet for this article.
August 2014: Journal of Thoracic and Cardiovascular Surgery
Lenard Conradi, Benjamin Kloth, Moritz Seiffert, Johannes Schirmer, Dietmar Koschyk, Stefan Blankenberg, Hermann Reichenspurner, Patrick Diemert, Hendrik Treede
AIMS: Recently, the feasibility of valve-in-valve procedures using current first-generation transcatheter heart valves (THV) in cases of structural valve degeneration has been reported as an alternative to conventional open repeat valve replacement. By design, certain biological valve xenografts carry a high risk of coronary ostia occlusion due to lateral displacement of leaflets after valve-in-valve procedures. In the present report we aimed to prove feasibility and safety of transapical valve-in-valve implantation of the JenaValve THV in two cases of degenerated Mitroflow bioprostheses...
December 2014: EuroIntervention
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"